News

PipelineReview.com23d
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Pipelinereview
about alyftrek and trikafta in the u.s. ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive ...
The Pharma Letter24d
Vertex presents new data on benefits of Alyftrek
This article is accessible to registered users, to continue reading please register for free.. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the ...
AFP24d
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - AFP.com
Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every ...
Seeking Alpha1mon
Vertex Pharmaceuticals, Inc. (VRTX) Q1 2025 Earnings Call Transcript
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ETCompany ParticipantsSusie Lisa - SVP, IRReshma Kewalramani ...
Investing1mon
Vertex Q1 2025 slides: Revenue hits $2.77B as product portfolio diversifies - Investing.com
The company’s flagship cystic fibrosis treatment TRIKAFTA/KAFTRIO generated $2.54 billion, while newly launched ALYFTREK contributed $54 million in its initial quarter on the market. Other ...
precisionmedicineonline6mon
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is under regulatory review in the EU, UK, Canada, Switzerland, Australia, and New Zealand. Separately, the FDA expanded the indication for Vertex's Trikafta on Friday to include cystic ...
BioSpace6mon
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - BioSpace
“In Phase 3 clinical trials, across a broad range of genotypes, once-daily ALYFTREK demonstrated non-inferiority to TRIKAFTA in ppFEV 1 response and statistically significant improvement in SwCl, a ...
Global News7mon
Saskatchewan expands Trikafta coverage for cystic fibrosis
“Trikafta reduced emergency room visits by 20 per cent,” he said. McEwan thanks the government for covering the drug in full for her, adding the increased coverage will help a lot of ...
The Globe and Mail7mon
Cystic fibrosis drug reduces hospital visits and offers patients hope – at a cost - at a cost - The Globe and Mail
New report finds that Trikafta patients’ admissions to hospital fell by an average of 65 per cent over one year – but at a list price of over $300,000, the drug is not yet considered cost ...
BioSpace9mon
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ...
Long-Term Benefits of TRIKAFTA ® Vertex will present new data on TRIKAFTA ® from long-term (96 week and 192 week) studies in patients ages 2-11 years old that reinforce the sustained benefit seen in ...
Yahoo Finance9mon
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American ... - Yahoo Finance
– Phase 3 data on investigational vanza triple demonstrates non-inferiority to TRIKAFTA ® in ppFEV 1 and further improvement of CFTR function as measured by sweat chloride – – Real-world evidence and ...